文献速递肿瘤 PET/CT放射性药物与辐射防护

高剂量糖皮质激素治疗三天可减轻大血管巨细胞动脉炎的大血管18F-FDG摄取,但对诊断准确性的影响有限

Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-18

前瞻性纳入24例新发并经PET/CT证实的大血管巨细胞动脉炎(LV-GCA)且未用过糖皮质激素的患者,所有患者每日口服泼尼松龙60 mg,分别在治疗3天(PET3)或10天(PET10)后行FDG PET/CT。治疗3天后10/10例仍可准确诊断LV-GCA,而治疗10天后仅5/14例可诊断(p < 0.001),提示3天内FDG PET/CT仍保持高敏感度。

要点

  • 治疗3天后FDG PET/CT可准确诊断10/10例LV-GCA,10天后仅5/14例可诊断(p < 0.001)。
  • 糖皮质激素治疗可减轻大血管FDG摄取,但3天内对诊断准确性影响有限。
  • 读者间一致性为87%,Cohen加权kappa 0.70,未发现CRP与FDG摄取相关。

核心结论

  • 在高剂量糖皮质激素治疗3天内,FDG PET/CT能以高敏感度诊断LV-GCA,这一窗口期可确保及时开始糖皮质激素治疗以避免GCA的致残性并发症,同时对诊断准确性影响有限。
  • 治疗10天后,FDG PET/CT的敏感度显著下降。

研究设计与样本

  • 前瞻性纳入24例新发、未经糖皮质激素治疗且经PET/CT证实的LV-GCA患者(治疗前基线PET)。
  • 排除既往有GCA或风湿性多肌痛病史、有模拟LV-GCA的疾病以及正在接受免疫抑制治疗的患者。
  • 所有患者每日口服泼尼松龙60 mg,并分配在治疗3天(PET3)或10天(PET10)后接受FDG PET/CT检查。
  • 由两名对患者临床数据不知情的经验丰富的核医学医师采用视觉半定量方法审阅FDG PET/CT图像,并评估读者间可靠性。

主要发现

  • 糖皮质激素治疗可减轻大血管FDG摄取,但LV-GCA在治疗3天后10/10例患者中仍可准确诊断,而治疗10天后仅5/14例患者可诊断(p < 0.001)。
  • 读者间一致性为87%,Cohen加权kappa为0.70(一致性充分)。
  • 未发现CRP与FDG摄取之间存在相关性。
  • 主动脉和/或主动脉上分支壁内节段性且均匀的FDG摄取,且摄取强度高于肝脏,被认为符合血管炎。

关键数值与推荐

  • 诊断标准:主动脉和/或主动脉上分支壁内节段性且均匀的FDG摄取,且摄取强度高于肝脏,被认为符合血管炎。
  • 治疗3天后FDG PET/CT准确诊断10/10例LV-GCA患者。
  • 治疗10天后FDG PET/CT准确诊断5/14例LV-GCA患者(p < 0.001)。
  • 读者间一致性87%,Cohen加权kappa 0.70。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the in-treatment diagnostic accuracy of FDG PET/CT in large-vessel giant cell arteritis (LV-GCA) by serial scans before and after a short course of high-dose glucocorticoid treatment. METHODS: Twenty-four glucocorticoid-naïve patients with new-onset PET/CT verified LV-GCA (pre-treatment baseline PET) were prospectively included. Excluded were patients with a previous history of GCA or polymyalgia rheumatica, LV-GCA-mimicking conditions and patients on immunosuppressive therapy. All patients were treated with 60 mg of oral prednisolone daily and assigned for in-treatment FDG PET/CT after either 3 (PET3) or 10 days (PET10). Two experienced nuclear medicine physicians, blinded to patients' clinical data, reviewed the FDG PET/CT images. A visual semi-quantitative approach was used. Segmental and homogenous FDG uptake in the wall of the aorta and/or supra-aortic branches with higher uptake intensity than liver was considered consistent with vasculitis. Inter-reader reliability was evaluated. RESULTS: Although glucocorticoid treatment attenuated FDG uptake in large vessels, LV-GCA was accurately diagnosed in 10/10 patients after 3 days of treatment, but only in 5/14 patients after 10 days of treatment (p < 0.001). Interrater reliability was substantial (agreement 87%, Cohen's weighted kappa 0.70). No correlation between CRP and FDG uptake was found. CONCLUSIONS: Within 3 days of high-dose glucocorticoid treatment, FDG PET/CT can diagnose LV-GCA with high sensitivity. This window of opportunity ensures that prompt glucocorticoid treatment can be initiated to avoid debilitating GCA complications with a limited effect on diagnostic accuracy. After 10 days of treatment, FDG PET/CT sensitivity decreases significantly.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Nielsen BD, Gormsen LC, Hansen IT, et al. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2018. PMID: 29671039. doi:10.1007/s00259-018-4021-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。